BD FACSDuet™ system raises the bar on flow cytometry automation offering a fully integrated sample-to-answer solution with the BD FACSLyric™ clinical flow cytometer
FRANKLIN LAKES, N.J., March 26, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today announced the CE-IVD certification for the BD FACSDuet™ automated flow cytometry system. The new fully automated sample preparation instrument enables clinical laboratories to improve their efficiency by reducing errors and limiting the manual user interactions required to run assays on the BD FACSLyric™ clinical flow cytometer.
The BD FACSDuet™ system builds new capabilities into the BD portfolio of clinical flow cytometry solutions. Collectively, these solutions may help clinical laboratories improve accuracy and repeatability of their assays by minimizing manual steps that can introduce errors.
"The BD FACSDuet system enables us to increase our laboratory's efficiency and throughput, replacing manual processes with automated ones that are traceable and that can be automatically transferred and recorded in our laboratory information system providing a complete audit trail," said David Bloxham, principal biomedical scientist at the Hemato-Oncology Diagnostic Service (HODS) at Cambridge University Hospital NHS Trust.
Physical integration between the BD FACSDuet™ system and the BD FACSLyric™ clinical flow cytometer allows technicians to load samples and reagents onto the BD FACSDuet™ system and receive data once the samples are fully processed from the BD FACSLyric™ clinical flow cytometer. Data integration using the BD FACSLink™ middleware solution, offers bidirectional communication between the instruments and connectivity with laboratory information systems (LIS).
"The introduction of the BD FACSDuet system is the natural continuation of our 40 year history of making reliable flow cytometry solutions that are more robust and easier to use," said John Ledek, worldwide president of Biosciences for BD. "Automation solutions for flow cytometry can go a long way towards improving accuracy and standardization from instrument to instrument providing the consistent results that clinicians depend on to inform patient care."
The BD FACSDuet™ automated flow cytometry system is available as an in vitro diagnostic (IVD) instrument in Europe and is targeted to be available in other geographies as soon as regulatory milestones are secured. The current platform automates the lyse-no-wash process. Existing systems can be field upgradeable as laboratory needs evolve. For more information, visit bdbiosciences.com/eu
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com.
Monique N. Dolecki
BD Public Relations
BD Investor Relations
View original content to download multimedia:http://www.prnewswire.com/news-releases/bd-launches-new-automated-flow-cytometry-sample-preparation-instrument-with-ce-ivd-certification-300818084.html